<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<!-- saved from url=(0146)http://www.clinicalevidenceonline.org/lpBinCE/lpext.dll/BMJSPLITCE/endocrine_disorders.html/0601/0601_q6/0601_i2?fn=document-frame.htm&f=templates -->
<HTML><HEAD><TITLE>Clinical Evidence</TITLE>
<META http-equiv=Content-Type content="text/html; charset=windows-1252"><LINK 
href="0601_i2_files/bmj.css" type=text/css rel=stylesheet>
<META content="MSHTML 5.50.4807.2300" name=GENERATOR></HEAD>
<BODY topMargin=0>
<TABLE cellSpacing=0 borderColorDark=#ffffff cellPadding=0 width="100%" 
borderColorLight=#c2c2c2 border=1>
  <TBODY>
  <TR>
    <TD class=heading id=heading>
      <SCRIPT src="0601_i2_files/0601_i2.0"></SCRIPT>

      <SCRIPT language=JavaScript> function showWindow(targeturl) { window.open(targeturl, ""); } </SCRIPT>

      <TABLE width="100%" border=0>
        <TBODY>
        <TR>
          <TD align=right><SPAN class=localheadtopic 
            id=localheadtopic><SECTION>Endocrine disorders</SECTION></SPAN><IMG 
            height=10 src="0601_i2_files/spacer.gif" width=10 align=absMiddle 
            border=0><BR><SPAN class=localhead 
            id=localhead><TOPIC>Cardiovascular disease in diabetes</TOPIC><IMG 
            height=10 src="0601_i2_files/spacer.gif" width=10 align=absMiddle 
            border=0></SPAN></TD></TR>
        <TR>
          <TD class=title-author id=title-author vAlign=top noWrap align=right 
          bgColor=#ffffff height=30><A 
            href="http://www.clinicalevidenceonline.org/lpBinCE/lpext.dll?f=id&amp;id=0601_CONTRIB&amp;t=document-frame.htm&amp;2.0&amp;p=">Ronald 
            Sigal and Janine Malcolm</A><IMG height=10 
            src="0601_i2_files/spacer.gif" width=10 align=absMiddle 
        border=0></TD></TR></TBODY></TABLE><BR>
      <H1 
      style="DISPLAY: none; FONT-SIZE: 0pt; VISIBILITY: hidden">Antihypertensives</H1>
      <TABLE cellSpacing=0 cellPadding=3 width="100%" border=0>
        <TBODY>
        <TR>
          <TD class=question id=question vAlign=top width="10%"><B><SPAN 
            class=question-title id=question-title>QUESTION</SPAN></B></TD>
          <TD class=question id=question>&nbsp;<B>What are the effects of 
            antihypertensive drugs in people with 
      diabetes?</B></TD></TR></TBODY></TABLE><BR><A name=I2>
      <H2 style="DISPLAY: none; FONT-SIZE: 0pt; VISIBILITY: hidden">Which 
      antihypertensive is best in diabetes?</H2>
      <TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
        <TBODY>
        <TR class=option id=option>
          <TD class=option id=option style="PADDING-LEFT: 2px" vAlign=top 
          width="10%"><SPAN class=option-title 
            id=option-title>OPTION&nbsp;&nbsp;&nbsp;</SPAN></TD>
          <TD class=option id=option style="PADDING-LEFT: 2px" 
            width="100%"><B>Different antihypertensive 
      drugs</B></TD></TR></TBODY></TABLE></A>
      <TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
        <TBODY>
        <TR>
          <TD><A name=I2-SUMSTATEMENT><B>
            <P style="MARGIN-LEFT: 3px" align=justify>One systematic review of 
            large RCTs has found that ACE inhibitors versus calcium channel 
            blockers as initial therapy for hypertension significantly reduce 
            cardiovascular events in people with type 2 diabetes aged 50–65 
            years. We found no clear evidence directly comparing ACE inhibitors 
            and diuretics. One large RCT found that an ACE inhibitor versus a ß 
            blocker had similar effect on cardiovascular events. One large RCT 
            has found that doxazosin (an &#945; blocker) versus chlortalidone 
            (chlorthalidone) (a diuretic) increases the risk of congestive heart 
            failure.</P></B></A></TD></TR></TBODY></TABLE><BR>
      <TABLE cellSpacing=0 cellPadding=3 width="100%" border=0>
        <TBODY>
        <TR>
          <TD>
            <P align=justify><FONT color=#0033cc><A 
            name=I2-BENEFITS><B>Benefits: </B></A></FONT>We found one systematic 
            review (search date 2000, 4 RCTs, 2180 people with diabetes) <A 
            href="http://www.clinicalevidenceonline.org/lpBinCE/lpext.dll/BMJSPLITCE/endocrine_disorders.html/0601/0601_q6/0601_i2?fn=document-frame.htm&amp;f=templates#REF24">[24]</A> 
            and two subsequent RCTs. <A 
            href="http://www.clinicalevidenceonline.org/lpBinCE/lpext.dll/BMJSPLITCE/endocrine_disorders.html/0601/0601_q6/0601_i2?fn=document-frame.htm&amp;f=templates#REF25">[25]</A> 
            <A 
            href="http://www.clinicalevidenceonline.org/lpBinCE/lpext.dll/BMJSPLITCE/endocrine_disorders.html/0601/0601_q6/0601_i2?fn=document-frame.htm&amp;f=templates#REF26">[26]</A> 
            The systematic review compared ACE inhibitors (1133 people) versus 
            other antihypertensive drugs (diuretics, ß blockers, or calcium 
            channel blockers; 1047 people). <A 
            href="http://www.clinicalevidenceonline.org/lpBinCE/lpext.dll/BMJSPLITCE/endocrine_disorders.html/0601/0601_q6/0601_i2?fn=document-frame.htm&amp;f=templates#REF24">[24]</A> 
            <B>ACE inhibitors versus calcium channel blockers:</B> We found one 
            systematic review, <A 
            href="http://www.clinicalevidenceonline.org/lpBinCE/lpext.dll/BMJSPLITCE/endocrine_disorders.html/0601/0601_q6/0601_i2?fn=document-frame.htm&amp;f=templates#REF24">[24]</A> 
            which found two RCTs <A 
            href="http://www.clinicalevidenceonline.org/lpBinCE/lpext.dll/BMJSPLITCE/endocrine_disorders.html/0601/0601_q6/0601_i2?fn=document-frame.htm&amp;f=templates#REF27">[27]</A> 
            <A 
            href="http://www.clinicalevidenceonline.org/lpBinCE/lpext.dll/BMJSPLITCE/endocrine_disorders.html/0601/0601_q6/0601_i2?fn=document-frame.htm&amp;f=templates#REF28">[28]</A> 
            comparing ACE inhibitors versus calcium channel blockers in people 
            with diabetes, and one subsequent RCT <A 
            href="http://www.clinicalevidenceonline.org/lpBinCE/lpext.dll/BMJSPLITCE/endocrine_disorders.html/0601/0601_q6/0601_i2?fn=document-frame.htm&amp;f=templates#REF25">[25]</A> 
            comparing ACE inhibitors versus calcium channel antagonists versus 
            conventional treatment (ß blockers or hydrochlorothiazide plus 
            amiloride). The two RCTs in the systematic review found that ACE 
            inhibitors versus calcium channel blockers significantly reduced 
            cardiovascular events (34/424 [8%] with ACE inhibitor <EM>v</EM> 
            151/526 [16%] with calcium channel blocker; ARR 8%, 95% CI 4% to 
            13%; RR 0.49, 95% CI 0.33 to 0.72; NNT 13, 95% CI 7 to 25). ACE 
            inhibitors versus calcium channel blockers also reduced the three 
            outcomes of death, AMI, and stroke, but the reductions were not 
            significant. The subsequent RCT (6614 people, 719 with diabetes, 
            mean age 76 years, mean blood pressure 190/99&nbsp;mmHg) found 
            (among the subgroup of people with diabetes) no significant 
            difference in the incidence of major cardiovascular events over 4 
            years (64.2 events/1000 person years with ACE inhibitors <EM>v</EM> 
            67.7 with calcium antagonists <EM>v</EM> 75.0 with conventional 
            agents). <A 
            href="http://www.clinicalevidenceonline.org/lpBinCE/lpext.dll/BMJSPLITCE/endocrine_disorders.html/0601/0601_q6/0601_i2?fn=document-frame.htm&amp;f=templates#REF25">[25]</A> 
            <B>ACE inhibitors versus diuretics: </B>We found one systematic 
            review, <A 
            href="http://www.clinicalevidenceonline.org/lpBinCE/lpext.dll/BMJSPLITCE/endocrine_disorders.html/0601/0601_q6/0601_i2?fn=document-frame.htm&amp;f=templates#REF24">[24]</A> 
            which found no RCTs specifically comparing ACE inhibitors versus 
            diuretics in people with diabetes, but found one RCT (572 people, 
            6.1 years) comparing ACE inhibitors versus alternative treatment 
            that included ß blockers, combination ß blockers and diuretics, and 
            diuretics in people with and without diabetes. Fewer people 
            allocated to captopril experieinced AMI, stroke or death compared to 
            diuretics or ß blockers (43/263 [18%] with diuretics/ß blockers 
            <EM>v</EM> 30/309 [10%] with captopril; ARR 6.6%, 95 CI 1.1% to 
            12.2%; NNT 15). <A 
            href="http://www.clinicalevidenceonline.org/lpBinCE/lpext.dll/BMJSPLITCE/endocrine_disorders.html/0601/0601_q6/0601_i2?fn=document-frame.htm&amp;f=templates#REF24">[24]</A> 
            <B>ACE inhibitors versus ß blockers:</B> We found one systematic 
            review, which included one RCT (758 people, 456 cardiovascular 
            events) comparing an ACE inhibitor (captopril) versus a ß blocker 
            (atenolol) over 8.4 years. <A 
            href="http://www.clinicalevidenceonline.org/lpBinCE/lpext.dll/BMJSPLITCE/endocrine_disorders.html/0601/0601_q6/0601_i2?fn=document-frame.htm&amp;f=templates#REF29">[29]</A> 
            The RCT found that captopril versus atenolol did not significantly 
            reduce the number of cardiovascular events (102/400 [25.5%] with 
            captopril <EM>v</EM> 75/358 [20.9%] with atenolol; ARI +5%, 95% CI 
            –1% to +11%; RR 1.22, 95% CI 0.94 to 1.58). <B>Other comparisons: 
            </B>We found no systematic review but found one RCT <A 
            href="http://www.clinicalevidenceonline.org/lpBinCE/lpext.dll/BMJSPLITCE/endocrine_disorders.html/0601/0601_q6/0601_i2?fn=document-frame.htm&amp;f=templates#REF26">[26]</A> 
            (age <U>&gt;</U>&nbsp;55 years, with hypertension and either 
            previous CVD or at least 1 additional CVD risk factor) comparing 
            chlortalidone, doxazosin, amlodipine, and lisinopril. After 3.3 
            years of follow up there was no difference between doxazosin (3183 
            people with diabetes) and chlortalidone (5481 people) in the primary 
            outcome (fatal coronary heart disease [CHD] or non-fatal AMI), but 
            the doxazosin arm was terminated because of an excess risk of 
            combined CVD events (coronary heart disease death, non-fatal AMI, 
            stroke, revascularisation procedures, angina, congestive heart 
            failure, and peripheral vascular disease) compared with 
            chlortalidone (OR 1.24, 95% CI 1.12 to 1.38). The RCT is still in 
            progress. <A 
            href="http://www.clinicalevidenceonline.org/lpBinCE/lpext.dll/BMJSPLITCE/endocrine_disorders.html/0601/0601_q6/0601_i2?fn=document-frame.htm&amp;f=templates#REF26">[26]</A> 
            </P></TD></TR></TBODY></TABLE>
      <TABLE cellSpacing=0 cellPadding=3 width="100%" border=0>
        <TBODY>
        <TR>
          <TD>
            <P align=justify><FONT color=#0033cc><A name=I2-HARMS><B>Harms: 
            </B></A></FONT>In one RCT, people taking atenolol gained more weight 
            than those taking captopril (3.4&nbsp;kg with atenolol <EM>v</EM> 
            1.6&nbsp;kg with captopril, P&nbsp;=&nbsp;0.02). <A 
            href="http://www.clinicalevidenceonline.org/lpBinCE/lpext.dll/BMJSPLITCE/endocrine_disorders.html/0601/0601_q6/0601_i2?fn=document-frame.htm&amp;f=templates#REF29">[29]</A> 
            Over the first 4 years of the trial, people allocated to atenolol 
            had higher mean HbA1c (7.5% <EM>v</EM> 7.0%, P&nbsp;=&nbsp;0.004), 
            but there was no difference between groups over the subsequent 4 
            years. There was no difference between atenolol and captopril in 
            rates of hypoglycaemia, lipid concentrations, tolerability, blood 
            pressure lowering, or prevention of disease 
      events.</P></TD></TR></TBODY></TABLE>
      <TABLE cellSpacing=0 cellPadding=3 width="100%" border=0>
        <TBODY>
        <TR>
          <TD>
            <P align=justify><FONT color=#0033cc><A name=I2-COMMENT><B>Comment: 
            </B></A></FONT>We found evidence that ACE inhibitors are superior to 
            calcium channel blockers as initial therapy. We found no clear 
            evidence directly comparing ACE inhibitors and diuretics. It is 
            unclear whether ACE inhibitors or ß-blockers are superior to each 
            other. In most trials, combination therapy with more than one agent 
            was required to achieve target blood 
      pressures.</P></TD></TR></TBODY></TABLE><BR><A name=references></A>
      <TABLE cellSpacing=0 cellPadding=0 border=0>
        <TBODY>
        <TR>
          <TD width=90 bgColor=#404040><IMG height=2 src="" width=1 
            align=absMiddle border=0></TD>
          <TD vAlign=bottom width="100%" bgColor=#404040><IMG height=2 src="" 
            width=1 align=absMiddle border=0></TD></TR>
        <TR>
          <TD class=key-message id=key-message width=90 
            bgColor=#404040><B>References</B></TD>
          <TD width="100%">&nbsp;</TD></TR></TBODY></TABLE><BR>
      <TABLE cellPadding=2 width="100%" align=center>
        <TBODY>
        <TR><A class=reference id=reference name=REF24>
          <TD class=reference id=reference vAlign=top width=15>24. </TD>
          <TD class=reference id=reference vAlign=top width="100%">Pahor M, 
            Psaty BM, Alderman MH, Applegate WB, Williamson JD, Furberg CD. 
            Therapeutic benefits of ACE inhibitors and other antihypertensive 
            drugs in patients with type 2 diabetes. <EM>Diabetes Care</EM> 
            2000;23:888–892. Search date January 2000; primary source Medline. 
            <A style="FONT-SIZE: 8pt" 
            href='javascript:showWindow("http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20352720");'>[PubMed]</A></TD></TR>
        <TR></A><A class=reference id=reference name=REF25>
          <TD class=reference id=reference vAlign=top width=15>25. </TD>
          <TD class=reference id=reference vAlign=top width="100%">Lindholm 
            LH, Hansson L, Ekbom T, et al. Comparison of antihypertensive 
            treatment in preventing cardiovascular events in elderly diabetic 
            patients: results from the Swedish trial in old patients with 
            hypertension–2. <EM>J Hypertens</EM> 2000;18:1671–1675. <A 
            style="FONT-SIZE: 8pt" 
            href='javascript:showWindow("http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20532032");'>[PubMed]</A></TD></TR>
        <TR></A><A class=reference id=reference name=REF26>
          <TD class=reference id=reference vAlign=top width=15>26. </TD>
          <TD class=reference id=reference vAlign=top width="100%">ALLHAT 
            Collaborative Research Group. Major cardiovascular events in 
            hypertensive patients randomised to doxazosin vs chlorthalidone: the 
            antihypertensive and lipid-lowering treatment to prevent heart 
            attack trial (ALLHAT). <EM>JAMA</EM> 2000;283:1967–1975. <A 
            style="FONT-SIZE: 8pt" 
            href='javascript:showWindow("http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20248526");'>[PubMed]</A></TD></TR>
        <TR></A><A class=reference id=reference name=REF27>
          <TD class=reference id=reference vAlign=top width=15>27. </TD>
          <TD class=reference id=reference vAlign=top width="100%">Estacio RO, 
            Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared 
            with enalapril on cardiovascular events in patients with 
            non-insulin-dependent diabetes and hypertension. <EM>N Engl J 
            Med</EM> 1998;338:645–652. <A style="FONT-SIZE: 8pt" 
            href='javascript:showWindow("http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=98135519");'>[PubMed]</A></TD></TR>
        <TR></A><A class=reference id=reference name=REF28>
          <TD class=reference id=reference vAlign=top width=15>28. </TD>
          <TD class=reference id=reference vAlign=top width="100%">Tatti P, 
            Pahor M, Byington RP, et al. Outcome results of the Fosfinopril 
            versus Amlodipine Cardiovascular Events randomised Trial (FACET) in 
            patients with hypertension and NIDDM. <EM>Diabetes</EM><EM>Care</EM> 
            1998;21:597–603.</TD></TR>
        <TR></A><A class=reference id=reference name=REF29>
          <TD class=reference id=reference vAlign=top width=15>29. </TD>
          <TD class=reference id=reference vAlign=top width="100%">UK 
            Prospective Diabetes Study Group. Efficacy of atenolol and captopril 
            in reducing risk of macrovascular and microvascular complications in 
            type 2 diabetes: UKPDS 39. <EM>BMJ</EM> 1998;317:713–720. <A 
            style="FONT-SIZE: 8pt" 
            href='javascript:showWindow("http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=98404065");'>[PubMed]</A></TD></TR></TBODY></TABLE>
      <TABLE width="100%" border=0>
        <TBODY>
        <TR>
          <TD vAlign=bottom width="50%">
          <TD align=right width="50%"><A 
            href="http://www.clinicalevidenceonline.org/lpBinCE/lpext.dll?f=id&amp;id=201106&amp;t=document-frame.htm&amp;p=copyright.html&amp;2.0"><IMG 
            alt="BMJ - Clinical Evidence" src="0601_i2_files/ce-pagebrand.jpg" 
            border=0></A></TD></TR>
        <TR>
          <TD align=left width="50%">
          <TD align=right width="50%"><A 
            href="http://www.clinicalevidenceonline.org/lpBinCE/lpext.dll?f=id&amp;id=201106&amp;t=document-frame.htm&amp;p=copyright.html&amp;2.0"><SPAN 
            style="FONT-SIZE: 8pt; font-face: arial">© 2001 BMJ Publishing 
            Group</SPAN></A></TD></TR></TBODY></TABLE>
      <SCRIPT language=JavaScript>
			var purl = "0601.PDF"; 
</SCRIPT>

      <SCRIPT language=JavaScript src="0601_i2_files/stats.js" 
      type=text/javascript></SCRIPT>

      <SCRIPT language=JavaScript type=text/javascript><!--
  stats("MC-MTg0OQ==-45MT-Y2Nz","","","");
//--></SCRIPT>
      <NOSCRIPT><IMG height=1 src="" width=1 
  border=0></NOSCRIPT></A></TD></TR></TBODY></TABLE>
<FORM name=LPHitCountForm><INPUT type=hidden value=0 name=LPHitCount> 
</FORM></BODY></HTML>
